|
[1] LIN CL, KAO JH. Hepatitis B virus genotypes and variants[J]. Cold Spring Harb Perspect Med, 2015, 5 (5) :a021436.
|
|
[2] MACLACHLAN JH, COWIE BC. Hepatitis B virus epidemiolo-gy[J]. Cold Spring Harb Perspect Med, 2015, 5 (5) :a021410.
|
|
[3] SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estima-tions of worldwide prevalence of chronic hepatitis B virus infec-tion:A systematic review of data published between 1965 and2013[J]. Lancet, 2015, 386 (10003) :1546-1555.
|
|
[4] PETRUZZIELLO A. Epidemiology of hepatitis B Virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma[J]. Open Virol J, 2018, 12:26-32.
|
|
[5] WANG SH, YEH SH, LIN WH, et al. Estrogen receptor alpharepresses transcription of HBV genes via interaction with hepa-tocyte nuclear factor 4alpha[J]. Gastroenterology, 2012, 142 (4) :989-998.
|
|
[6] FENG H, CHENG ASL, TSANG DP, et al. Cell cycle-relatedkinase is a direct androgen receptor-regulated gene thatdrivesβ-catenin/T cell factor-dependent hepatocarcinogen-esis[J]. J Clin Invest, 2011, 121 (8) :3159-3175.
|
|
[7] CHEN DS. Fighting against viral hepatitis:Lessons from Tai-wan[J]. Hepatology, 2011, 54 (2) :381-392.
|
|
[8] MARENGO A, ROSSO C, BUGIANESI E. Liver cancer:Con-nections with obesity, fatty liver, and cirrhosis[J]. Annu RevMed, 2016, 67:103-117.
|
|
[9] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J].Lancet, 2018, 391 (10127) :1301-1314.
|
|
[10] FRANCESCHI S, MONTELLA M, POLESEL J, et al. Hepatitisviruses, alcohol, and tobacco in the etiology of hepatocellularcarcinoma in Italy[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15 (4) :683-689.
|
|
[11] BALOGH J, VICTOR D 3rd, ASHAM EH, et al. Hepatocellularcarcinoma:A review[J]. J Hepatocell Carcinoma, 2016, 3:41-53.
|
|
[12] Crissien AM, Frenette C. Current management of hepatocellu-lar carcinoma[J]. Gastroenterol Hepatol, 2014, 10 (3) :153-161.
|
|
[13] CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carci-noma across a biological gradient of serum hepatitis B virusDNA level[J]. JAMA, 2006, 295 (1) :65-73.
|
|
[14] MCMAHON BJ. The natural history of chronic hepatitis B virusinfection[J]. Hepatology, 2009, 49 (5 Suppl) :s45-s55.
|
|
[15] SUNG WK, ZHENG H, LI S, et al. Genome-wide survey ofrecurrent HBV integration in hepatocellular carcinoma[J]. NatGenet, 2012, 44 (7) :765-769.
|
|
[16] PARK YM, JANG JW, YOO SH, et al. Combinations of eightkey mutations in the X/preC region and genomic activity ofhepatitis B virus are associated with hepatocellular carcinoma[J]. J Viral Hepat, 2014, 21 (3) :171-177.
|
|
[17] DONATO F, TAGGER A, GELATTI U, et al. Alcohol and hep-atocellular carcinoma:The effect of lifetime intake and hepatitisvirus infections in men and women[J]. Am J Epidemiol, 2002, 155 (4) :321-323.
|
|
[18] XU HZ, LIU YP, GULENG B, et al. Hepatitis B virus-relatedhepatocellular carcinoma:Pathogenic mechanisms and noveltherapeutic interventions[J]. Gastrointest Tumors, 2014, 1 (3) :135-145.
|
|
[19] TOYODA H, KUMADA T, TADA T, et al. Risk factors of hepa-tocellular carcinoma development in non-cirrhotic patientswith sustained virologic response for chronic hepatitis C virusinfection[J]. J Gastroenterol Hepatol, 2015, 30 (7) :1183-1189.
|
|
[20] ZHANG XM, WEI MJ, XU ZJ, et al. Pattern of serumα-fetalprotein, intereleukin-6 and Golgi protein 73 expressed in liverdiseases and their diagnostic value on hepatocellular carcino-ma[J/CD]. Chin J Exp Clin Infect Dis:Electronic Edition, 2017, 11 (4) :339-344. (in Chinese) 张小曼, 魏梅娟, 许正锯, 等.血清甲胎蛋白、白细胞介素-6和高尔基体蛋白73在肝脏疾病中的表达特点及其对肝细胞癌的诊断价值[J/CD].中华实验和临床感染病杂志:电子版, 2017, 11 (4) :339-344.
|
|
[21] MCMAHON BJ, BULKOW L, HARPSTER A, et al. Screeningfor hepatocellular carcinoma in Alaska Natives infected withchronic hepatitis B:A 16-year population-based study[J].Hepatology, 2000, 32 (4) :842-846.
|
|
[22] JANG ES, JEONG SH, KIM JW, et al. Diagnostic perform-ance of alpha-fetoprotein, protein induced by vitamin K ab-sence, osteopontin, dickkopf-1 and its combinations for hep-atocellular carcinoma[J]. PLo S One, 2016, 11 (3) :e0151069.
|
|
[23] KANG XY, YIN ZF, QIAN HH, et al. Correlation between ser-um alpha-fetoprotein variantlevels in patients with hepatocel-lular carcinoma and the presence of alpha-fetoprotein mR-NAin the circulating blood[J]. Chin J Hepatol, 2003, 11 (1) :17-19. (in Chinese) 康晓燕, 殷正丰, 钱海华, 等.肝癌患者外周血甲胎蛋白异质体和转录物含量的相关分析[J].中华肝脏病杂志, 2003, 11 (1) :17-19.
|
|
[24] ZHU R, YANG J, XU L, et al. Diagnostic performance of des-γ-carboxy prothrombin for hepatocellular carcinoma:Ameta-analysis[J]. Gastroenterol Res Pract, 2014, 2014:529314.
|
|
[25] SONG P, FENG X, INAGAKI Y, et al. Clinical utility of simultane-ous measurement of alpha-fetoprotein and des-γ-carboxyprothrombin for diagnosis of patients with hepatocellular carcino-ma in China:A multi-center case-controlled study of 1, 153subjects[J]. Biosci Trends, 2014, 8 (5) :266-273.
|
|
[26] LU FM. Serological diagnosis of hepatocellular carcinoma:Chal-lenges and opportunities[J]. J Clin Hepatol, 2017, 33 (7) :1262-1265. (in Chinese) 鲁凤民.肝细胞癌的血清学诊断———挑战与希望同在[J].临床肝胆病杂志, 2017, 33 (7) :1262-1265.
|
|
[27] MOSSAD NA, MAHMOUD EH, OSMAN EA, et al. Evaluationof squamous cell carcinoma antigen-immunoglobulin M com-plex (SCCA-IGM) and alpha-L-fucosidase (AFU) as no-vel diagnostic biomarkers for hepatocellular carcinoma[J].Tumour Biol, 2014, 35 (11) :11559-11564.
|
|
[28] PARK SJ, LEE SK, LIM CR, et al. Heme oxygenase-1/car-bon monoxide axis suppresses transforming growth factor-beta1-induced growth inhibition by increasing ERK1/2-me-diated phosphorylation of Smad3 at Thr-179 in human hepa-tocellular carcinoma cell lines[J]. Biochem Biophys Res Com-mun, 2018, 498 (3) :609-615.
|
|
[29] BOLONDI L, SOFIA S, SIRINGO S, et al. Surveillance pro-gramme of cirrhotic patients for early diagnosis and treatmentof hepatocellular carcinoma:A cost effectiveness analysis[J].Gut, 2001, 48 (2) :251-259.
|
|
[30] ZHANG BH, YANG BH, TANG ZY. Randomized controlled tri-al of screening for hepatocellular carcinoma[J]. J Cancer ResClin Oncol, 2004, 130 (7) :417-422.
|
|
[31] CHANG MH, YOU SL, CHEN CJ, et al. Long-term effects ofhepatitis B immunization of infants in preventing liver cancer[J]. Gastroenterology, 2016, 151 (3) :472-480.
|
|
[32] LIN CL, KAO JH. Review article:Novel therapies for hepatitisB virus cure-advances and perspectives[J]. Aliment Phar-macol Ther, 2016, 44 (3) :213-222.
|
|
[33] YUAN G, HU AR, HU YR, et al. Clinical effect of entecavirand adefovir dipivoxil in treatment of compensated hepatitis Bcirrhosis and long-term prognosis[J]. Chin J Clin PharmacolTher, 2018, 23 (2) :170-174. (in Chinese) 袁刚, 胡爱荣, 胡耀仁, 等.恩替卡韦和阿德福韦酯治疗代偿期乙肝肝硬化临床疗效及远期预后[J].中国临床药理学与治疗学, 2018, 23 (2) :170-174.
|
|
[34] ZHANG QQ, AN X, LIU YH, et al. Long-term nucleos (t) ideanalogues therapy for adults with chronic hepatitis B reducesthe risk of long-term complications:A meta-analysis[J].Virol J, 2011, 8:72.
|
|
[35] LAI CL, YUEN MF. Prevention of hepatitis B virus-relatedhepatocellular carcinoma with antiviral therapy[J]. Hepatolo-gy, 2013, 57 (1) :399-408.
|
|
[36] DARGAN A, WONG SY, COBEN R, et al. Persistent risk forhepatocellular carcinoma after more than a decade of suc-cessful hepatitis B virus suppression[J]. Minerva Gastroen-terol Dietol, 2017, 63 (1) :74-76.
|
|
[37] TAVAKOLPOUR S, MIRSAFAEI HS, ELKAEI BEHJATI S, et al.Toward cure chronic hepatitis B infection and hepatocellularcarcinoma prevention:Lessons learned from nucleos (t) ideanalogues therapy[J]. Immunol Lett, 2017, 190:206-212.
|
|
[38] SU TH, TSENG TC, KAO JH. HCC risk in patients with HBV-related cirrhosis receiving NA therapy:Is HCC prevented ordelayed?[J]. Hepatology, 2018, 67 (4) :1634-1635.
|
|
[39] SASAKI K, SHINDOH J, NISHIOKA Y, et al. Impact of viral e-tiology on postoperative de novo recurrence after hepatectomyfor hepatocellular carcinoma in cirrhotic patients[J]. J Gas-trointest Surg, 2017, 21 (3) :487-495.
|
|
[40] SUN P, DONG X, CHENG X, et al. Nucleot (s) ide analoguesfor hepatitis B virus-related hepatocellular carcinoma aftercurative treatment:A systematic review and meta-analysis[J]. PLo S One, 2014, 9 (7) :e102761.
|
|
[41] LEE PC, YEH CM, HU YW, et al. Antiplatelet therapy is asso-ciated with a better prognosis for patients with hepatitis B virus-related hepatocellular carcinoma after liver resection[J].Ann Surg Oncol, 2016, 23 (Suppl 5) :874-883.
|
DownLoad: